Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2008

Open Access 01-12-2008 | Research

Downregulation of CD147 expression alters cytoskeleton architecture and inhibits gelatinase production and SAPK pathway in human hepatocellular carcinoma cells

Authors: Ai-Rong Qian, Wei Zhang, Jian-Ping Cao, Peng-Fei Yang, Xiang Gao, Zhe Wang, Hui-Yun Xu, Yuan-Yuan Weng, Peng Shang

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2008

Login to get access

Abstract

Background

CD147 plays a critical role in the invasive and metastatic activity of hepatocellular carcinoma (HCC) cells by stimulating the surrounding fibroblasts to express matrix metalloproteinases (MMPs). Tumor cells adhesion to extracellular matrix (ECM) proteins is the first step to the tumor metastasis. MMPs degrade the ECM to promote tumor metastasis. The aim of this study is to investigate the effects of small interfering RNA (siRNA) against CD147 (si-CD147) on hepatocellular carcinoma cells' (SMMC-7721) architecture and functions.

Methods

Flow cytometry and western blot assays were employed to detect the transfection efficiency of si-CD147. Confocal microscopy was used to determine the effects of si-CD147 on SMMC-7721 cells' cytoskeleton. Invasion assay, gelatin zymography and cell adhesion assay were employed to investigate the effects of si-CD147 on SMMC-7721 cells' invasion, gelatinase production and cell adhesive abilities. Western blot assay was utilized to detect the effects of si-CD147 on focal adhesion kinase (FAK), vinculiln and mitogen-activated protein kinase (MAPK) expression in SMMC-7721 cells.

Results

Downregulation of CD147 gene induced the alteration of SMMC-7721 cell cytoskeleton including actin, microtubule and vimentin filaments, and inhibited gelatinase production and expression, cells invasion, FAK and vinculin expression. si-CD147 also blocked SMMC-7721 cells adhesion to collagen IV and phosphorylation level of SAPK/JNKs. SAPK/JNKs inhibitor SP600125 inhibited gelatinase production and expression.

Conclusion

CD147 is required for normal tumor cell architecture and cell invasion. Downregulation of CD147 affects HCC cell structure and function. Moreover, the alteration of cell behavior may be related to SAPK/JNK Pathway. siRNA against CD147 may be a possible new approach for HCC gene therapy.
Appendix
Available only for authorised users
Literature
1.
Yan L, Zucker S, Toole BP: Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost. 2005, 93: 199-204.
2.
Guo H, Li R, Zucker S, Toole BP: EMMPRIN (CD147), an inducer of matrix metallo proteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Cancer Res. 2000, 60: 888-891.
3.
Kanekura T, Chen X, Kanzaki T: Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer. 2002, 99: 520-528. 10.1002/ijc.10390.CrossRef
4.
Ochrietor JD, Moroz TP, van Ekeris L, Clamp MF, Jefferson SC, deCarvalho AC: Retina-specific expression of 5A11/Basigin-2, a member of the immunoglobulin gene superfamily. Invest Ophthalmol Vis Sci. 2003, 44: 4086-4096. 10.1167/iovs.02-0995.CrossRef
5.
Spring FA, Holmes CH, Simpson KL, Mawby WJ, Mattes MJ, Okubo Y, Parsons SF: The Oka blood group antigen is a marker for the M6 leukocyte activation antigen, the human homolog of OX-47 antigen, basigin and neurothelin, an immunoglobulin superfamily molecule that is widely expressed in human cells and tissues. Eur J Immunol. 1997, 27: 891-897. 10.1002/eji.1830270414.CrossRef
6.
Sun J, Hemler ME: Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res. 2001, 61: 2276-2281. [PMID: 11280798]
7.
Muramatsu T, Miyauchi T: Basigin (CD147): a multifunctional trans-membrane protein involved in reproduction, neural function, inflammation and tumor invasion. Histol Histopathol. 2003, 18: 981-987.
8.
Lim M, Martinez T, Jablons D, Cameron R, Guo H, Toole B: Tumor-derived EMMPRIN (extracellular matrix metalloproteinase inducer) stimulates collagenase transcription through MAPK p38. FEBS Lett. 1998, 441: 88-92. 10.1016/S0014-5793(98)01474-4.CrossRef
9.
Li Y, Shang P, Qian AR, Wang L, Yang Y, Chen ZN: Inhibitory effects of antisense RNA of HAb18G/CD147 on invasion of hepatocellular carcinoma cells in vitro. World J Gastroenterol. 2003, 9: 2174-2177.
10.
Jiang JL, Zhou Q, Yu MK, Ho LS, Chen ZN, Chan HC: The involvement of HAb18G/CD147 in regulation of store-operated calcium entry and metastasis of human hepatoma cells. J Biol Chem. 2001, 276: 46870-46877. 10.1074/jbc.M108291200.CrossRef
11.
Chen ZN, Qian AR, Shang P, Huang BC, Zhu P: HAb18G/CD147 antagonistic peptides targeting Human Hepatocellular Carcinoma Cell Membrane Antigen HAb18G/CD147. J Tumor Marker Oncol. 2003, 18: 5-18.
12.
Qian AR, Shan P, Chen T, Chen ZN: Preparation of HAb18G/CD147 Antagonistic Peptide AP-9 Modified by Poly – ethylene Glycol. J Tumor Marker Oncol. 2003, 18: 371-380.
13.
Qian AR, Shang P, Luo ZQ, Chen ZN: A combined bioinformatic approach oriented to analyze HAb18G/CD147 antagonistic peptides characteristics. J Tumor Marker Oncol. 2003, 18: 29-36.
14.
Mueller MM, Fusenig Nt E: Friends or foes – bipolar effects of the tumour stroma in cancer. Nature Rev Cancer. 2004, 4: 839-849. 10.1038/nrc1477.CrossRef
15.
Kiaris H, Chatzistamou I, Kalofoutis Ch, Koutselini H, Piperi Ch, Kalofoutis A: Tumour-stroma interactions in carcinogenesis: Basic aspects and perspectives. Mol Cell Biochem. 2004, 26: 117-122. 10.1023/B:MCBI.0000028746.54447.6c.CrossRef
16.
Bannigan A, Lizotte-Waniewski M, Riley M, Baskin TI: Emerging molecular mechanisms that power and regulate the anastral mitotic spindle of flowering plants. Cell Motil Cytoskel. 2008, 65: 1-11. 10.1002/cm.20247.CrossRef
17.
Lauffenburger DA, Horwitz AF: Cell migration: A physically integrated molecular process. Cell. 1996, 84: 359-369. 10.1016/S0092-8674(00)81280-5.CrossRef
18.
Janssen ME, Kim E, Liu H, Fujimoto LM, Bobkov A, Volkmann N, Hanein D: Three-dimensional structure of vinculin bound to actin filaments. Mol Cell. 2006, 21: 271-281. 10.1016/j.molcel.2005.11.020.CrossRef
19.
Nhieu GT, Izard T: Vinculin binding in its closed conformation by a helix addition mechanism. EMBO J. 2007, 26: 4588-4596. 10.1038/sj.emboj.7601863.CrossRef
20.
Wozniak MA, Modzelewska K, Kwong L, Keely PJ: Focal adhesion regulation of cell behavior. Biochim Biophys Acta. 2004, 1692: 103-119.CrossRef
21.
Mitra SK, Hanson DA, Schlaepfer DD: Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol. 2005, 6: 56-68. 10.1038/nrm1549.CrossRef
22.
Davis RJ: Signal Transduction by the JNK Group of MAP Kinases. Cell. 2000, 103: 239-252. 10.1016/S0092-8674(00)00116-1.CrossRef
23.
Victoria R, Jonathan H, Donald VG, Zita D, Carrie RS: MKK4 and metastasis suppression: A marriage of signal transduction and metastasis research. Clin Exp Metastasis. 2003, 20: 25-30. 10.1023/A:1022586318678.CrossRef
24.
Dykxhoorn DM, Novina CD, Sharp PA: Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol. 2003, 4: 457-467. 10.1038/nrm1129.CrossRef
25.
Xu HY, Qian AR, Shang P, Xu J, Kong LM, Bian HJ, Chen ZN: siRNA targeted against HAb18G/CD147 inhibits MMP-2 secretion, actin and FAK expression in hepatocellular carcinoma cell line via ERK1/2 pathway. Cancer Letters. 2007, 247: 336-344. 10.1016/j.canlet.2006.05.017.CrossRef
26.
Hotulainen P, Lappalainen P: Stress fibers are generated by two distinct actin assembly mechanisms in motile cells. J Cell Bio. 2006, 173: 383-94. 10.1083/jcb.200511093.CrossRef
27.
Tsai WC, Jin JS, Yu JC, Sheu LF: CD10, Actin, and Vimentin Expression in Breast Phyllodes Tumors Correlates with Tumor Grades of the WHO Grading System. Int J Surg Pathol. 2006, 14: 127-131. 10.1177/106689690601400204.CrossRef
28.
Anguelov Z: Cytoskeleton Proteins as Markers for an Enhanced Metastatic Potential: New Possibilities in Cancer Management. Currents. 2000, 1: 1-3.
29.
Singh S, Sadacharan S, Su S, Belldegrun A, Persad S, Singh G: Overexpression of Vimentin Role in the Invasive Phenotype in an Androgen-independent Model of Prostate Cancer. Cancer Research. 2003, 63: 2306-2311.
30.
Khunkeawla P, Moonsom S, Staffler G, Kongtawelert P, Kasinrerk W: Engagement of CD147 molecule-induced cell aggregation through the activation of protein kinases and reorganization of the cytoskeleton. Immunobiology. 2001, 203: 659-69.CrossRef
31.
Cho JY, Fox DA, Horejsi V, Sagawa K, Skubitz KM, Katz DR, Chain B: The functional interactions between CD98, β1-integrins, and CD147 in the induction of U937 homotypic aggregation. Blood. 2001, 98: 374-382. 10.1182/blood.V98.2.374.CrossRef
32.
Curtin KD, Meinertzhagen IA, Wyman RJ: Basigin (EMMPRIN/CD147) interacts with integrin to affect cellular architecture. J Cell Sci. 2005, 118: 2649-2660. 10.1242/jcs.02408.CrossRef
33.
Schlosshauer B, Bauch H, Frank R: Neurothelin: amino acid sequence, cell surface dynamics and actin colocalization. Eur J Cell Bio. 1995, 68: 159-166.
34.
Wang L, Wu G, Yu L, Yuan J, Fang F, Zhai Z, Wang F, Wang H: Inhibition of CD147 Expression Reduces Tumor Cell Invasion in Human Prostate Cancer Cell Line via RNA Interference. Cancer Biol Ther. 2006, 5: 608-14.CrossRef
35.
Kalluri R: Basement membranes: structure, assembly and role in tumor angiogenesis. Nat Rev Cancer. 2003, 3: 422-433. 10.1038/nrc1094.CrossRef
36.
Yang C, Zeisberg M, Lively JC, Nyberg P, Afdhal N, Kalluri R: Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. Cancer Res. 2003, 63: 8312-8317.
37.
Janssen ME, Kim E, Liu H, Fujimoto LM, Bobkov A, Volkmann N, Hanein D: Three-dimensional structure of vinculin bound to actin filaments. Mol Cell. 2006, 21: 271-281. 10.1016/j.molcel.2005.11.020.CrossRef
38.
Kuroda N, Naruse K, Miyazaki E, Hayashi Y, Yoshikawa C, Ashida S, Moriki T, Yamasaki Y, Numoto S, Yamamoto Y, Yamasaki I, Hiroi M, Shuin T, Enzan H: Vinculin: Its possible use as a marker of normal collecting ducts and renal neoplasms with collecting duct system phenotype. Mod Pathol. 2000, 13: 1109-1114. 10.1038/modpathol.3880205.CrossRef
39.
Carragher NO, Frame MC: Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion. Trends Cell Biol. 2004, 14: 241-249. 10.1016/j.tcb.2004.03.011.CrossRef
40.
Owens LV, Xu L, Craven RJ, Dent GA, Weiner TM, Kornberg L, Liu ET, Cance WG: Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res. 1995, 55: 2752-2755.
41.
Golubovskaya VM, Finch R, Kweh F, Massoll NA, Campbell-Thompson M, Wallace MR, Cance WG: p53 regulates FAK expression in human tumor cells. Mol Carcinog. 2008, 47: 373-382. 10.1002/mc.20395.CrossRef
42.
Lu Z, jiang G, Blume-Jensen P, Hunter T: Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol Cell Biol. 2001, 21: 4016-4031. 10.1128/MCB.21.12.4016-4031.2001.CrossRef
43.
Coso OA, Chiariello M, Yu JC, Teramoto H, Crespo P, Xu N, Miki T, Gutkind JS: The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell. 1995, 81: 1137-1146. 10.1016/S0092-8674(05)80018-2.CrossRef
44.
Simon C, Simon M, Vucelic G, Hicks MJ, Plinkert PK, Koitschev A, Zenner HP: The p38 SAPK pathway regulates the expression of the MMP-9 collagenase via AP-1-dependent promoter activation. Exp Cell Res. 2001, 271: 344-355. 10.1006/excr.2001.5374.CrossRef
Metadata
Title
Downregulation of CD147 expression alters cytoskeleton architecture and inhibits gelatinase production and SAPK pathway in human hepatocellular carcinoma cells
Authors
Ai-Rong Qian
Wei Zhang
Jian-Ping Cao
Peng-Fei Yang
Xiang Gao
Zhe Wang
Hui-Yun Xu
Yuan-Yuan Weng
Peng Shang
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2008
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-27-50

Other articles of this Issue 1/2008

Journal of Experimental & Clinical Cancer Research 1/2008 Go to the issue

Research

Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review

Research

Lipocalin 2 promotes lung metastasis of murine breast cancer cells

Research

Malignant lymphomas (ML) and HIV infection in Tanzania

Research

Gene expression subtraction of non-cancerous lung from smokers and non-smokers with adenocarcinoma, as a predictor for smokers developing lung cancer

Research

The withdrawal from oncogenetic counselling and testing for hereditary and familial breast and ovarian cancer. A descriptive study of an Italian sample

Research

Histological vis – a – vis biochemical assessment on the toxic level and antineoplastic efficacy of a synthetic drug Pt – ATP on experimental animal models
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits